New approaches in the therapy of the peripheral vascular ulcer.
Angiology, 1978/9;29(9):666-74.
Sawyer PN, Sophie MD, Dowbak MD, Cohen MD, Feller J
PMID: 101101
Impact factor: 3.299
Abstract
It can readily be seen that Debrisan represents a more effective mode of therapy for several groups of patients which tend to have chronic disabling ulcers of limbs of various etiologies, including venous stasis ulcers, chronic sickle-cell ulcers, decubiti, etc. The more effective treatment of this patient populations, which is provided by Debrisan, would provide a very significant decrease in the total cost of health care in the United States, approximating half a billion dollars per year.
MeSH terms
Adolescent; Dextrans; Female; Humans; Leg Ulcer; Long-Term Care; Middle Aged; Socioeconomic Factors; Time Factors; Veins
More resources
EndNote: Download